علاج سرطان المعدة المتقدم أو النقيلي: سلبي HER2 مع حالة MSI-H / dMMR

References

DOI: 10.1016/j.annonc.2022.07.004

1. Pembrolizumab is recommended for second-line treatment of patients with MSI-H/dMMR gastric cancer [II, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-B].
2. In the phase II KEYNOTE-158 trial, pembrolizumab monotherapy was highly active in patients with previously treated advanced MSI-H gastric cancer, demonstrating an ORR of 45.8% and a median PFS of 11 months, with median OS and median duration of response not yet reached.